tbuckley/cabot-search huggingface dataset:
Review: In patients with ureteric lithiasis, α-blockers increase stone expulsion
Authors: Matthew Thompson, Terry Scott
Journal: Annals of Internal Medicine (2017)

ACP Journal Club18 April 2017Review: In patients with ureteric lithiasis, α-blockers increase stone expulsionMatthew Thompson, MBChB, MPH, DPhil, Terry Scott, MPA, PA-CMatthew Thompson, MBChB, MPH, DPhilUniversity of Washington, Seattle, Washington, USA (M.T., T.S.)Search for more papers by this author, Terry Scott, MPA, PA-CUniversity of Washington, Seattle, Washington, USA (M.T., T.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-166-8-042 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationRaison N, Ahmed K, Brunckhorst O, Dasgupta P. Alpha blockers in the management of ureteric lithiasis: a meta-analysis. Int J Clin Pract. 2017;71:e12917. https://pubmed.ncbi.nlm.nih.gov/28097758Clinical Impact RatingsGIM/FP/GP: References1 Ghani KR, Roghmann F, Sammon JD, et al. Emergency department visits in the United States for upper urinary tract stones: trends in hospitalization and charges. J Urol. 2014;191:90-6. [PMID: 23933053] Google Scholar2 Preminger GM, Tiselius HG, Assimos DG, et al, EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. J Urol. 2007;178:2418-34. [PMID: 17993340] Google Scholar3 Sasaki S, Tomiyama Y, Kobayashi S, et al. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology. 2011;77:762.e13-7. [PMID: 21195469] Google Scholar4 Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015;386:341-9. [PMID: 25998582] Google Scholar5 Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. [PMID: 27908918] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Washington, Seattle, Washington, USA (M.T., T.S.)This article was published at Annals.org on 4 April 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 18 April 2017Volume 166, Issue 8Page: JC42KeywordsAnalgesiaConfidence intervalsMyalgiaNumber needed to treatRisk managementRisk ratioSmooth musclesSurgerySystematic reviewsUreter ePublished: 18 April 2017 Issue Published: 18 April 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCTAP C-285 Transseptal Transcatheter Mitral Valve-in-valve Replacement for a Failed Bioprosthetic Mitral Valve
Authors: Do-Yoon Kang, Hanbit Park, Sang-Cheol Cho, Osung Kwon, Ungjeong Do, Kyusup Lee, Jung Ae Hong, Se Hun Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2017)
Impact of single nucleotide polymorphism of cyclophosphamide metabolism gene in patients with diffuse large B-cell lymphoma on survival after chemotherapy.
Authors: Farhana Malik, Veronika Bachanova, Ryan Shanley, Lata Chauhan, Jatinder Kaur Lamba
Journal: Journal of Clinical Oncology (2014)

e13519 Background: Cyclophosphamide (Cy) is a prodrug metabolized in liver into active cytotoxin. Cy-containing chemotherapy is often curative for patients with diffuse large B Cell lymphoma (DLBCL); however, 50% of patients relapse. We investigated the association between genetic polymorphisms in Cy metabolism and outcomes after induction chemotherapy for DLBCL Methods: We studied 76 patients with DLBCL treated with standard dose Cy-containing regimens (Cy 500mg/m2) at the University of Minnesota. Somatic DNA was obtained from bone marrow aspirates, and Sequenom and Taqman genotyping assays were used to analyze 22 genes and 38 single nucleotide polymorphisms (SNP) involved in Cy metabolism. Two-year disease free survival (DFS) was compared using a Cox regression model for each SNP, adjusting for age (≥ 65) and gender. The odds of achieving complete remission (CR) were modeled using logistic regression. P-values were corrected for multiple testing using the Holm method. Results: Sixty-one patients (80%) achieved CR after completion of chemotherapy. A higher CR rate was associated with heterozygosity at the rs1051266 SNP compared to homozygosity at this SNP (CR rate 91% vs 59%); but the difference was not statistically significant. Median follow-up was 5.1 years, and 2-year DFS was 71% (95% CI: 59-80). None of 38 SNPs had an impact on DFS. Conclusions: The rs1051266 SNP is located in the SLC19A1 gene, which codes for a folate transporter. This SNP should be evaluated in larger studies to confirm its association with improved CR rate in DLBCL patients treated with Cy-containing chemotherapy.
International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12)
Authors: Joachim Weis, Krzysztof A. Tomaszewski, Eva Hammerlid, Juan Ignacio Arraras, Thierry Conroy, Anne Lanceley, Heike Schmidt, Markus Wirtz, Susanne Singer, Monica Pinto, Mohamed Alm El-Din, Inge Compter, Bernhard Holzner, Dirk Hofmeister, Wei-Chu Chie, Marek Czeladzki, Amelie Harle, Louise Jones, Sabrina Ritter, Hans-Henning Flechtner, Andrew Bottomley
Journal: JNCI Journal of the National Cancer Institute (2016)

The European Organisation for Research and Treatment of Cancer (EORTC) Group has developed a new multidimensional instrument measuring cancer-related fatigue to be used in conjunction with the quality of life core questionnaire (EORTC QLQ-C30). The module EORTC QLQ-FA13 assesses physical, cognitive, and emotional aspects of cancer-related fatigue.The methodology follows the EORTC guidelines for phase IV validation of modules. This paper focuses on the results of the psychometric validation of the factorial structure of the module. For validation and cross-validation confirmatory factor analysis (maximum likelihood estimation), intraclass correlation and Cronbach alpha for internal consistency were employed. The study involved an international multicenter collaboration of 11 European and non-European countries.A total of 946 patients with various tumor diagnoses were enrolled. Based on the confirmatory factor analysis, we could approve the three-dimensional structure of the module. Removing one item and reassigning the factorial mapping of another item resulted in the EORTC QLQ-FA12. For the revised scale, we found evidence supporting good local (indicator reliability ≥ 0.60, factor reliability ≥ 0.82) and global model fit (GFI t1|t2 = 0.965/0.957, CFI t1|t2 = 0.976/0.972, RMSEA t1|t2 = 0.060/0.069) for both measurement points. For each scale, test-retest reliability proved to be very good (intraclass correlation: R t1-t2 = 0.905-0.921) and internal consistency proved to be good to high (Cronbach alpha = .79-.90).Based on the former phase III module, the multidimensional structure was revised as a phase IV module (EORTC FA12) with an improved scale structure. For a comprehensive validation of the EORTC FA12, further aspects of convergent and divergent validity as well as sensitivity to change should be determined.
A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.
Authors: Giovanni Martinelli, Alberto M. Martelli, Tiziana Grafone, Irina Mantovani, Alessandra Cappellini, Pier Luigi Tazzari, Emanuela Ottaviani, Simona Soverini, Marilina Amabile, Matteo Renzulli, Carolina Terragna, Sabrina Colarossi, Ilaria Iacobucci, Angela Poerio, Michele Baccarani
Journal: Blood (2005)
CAG Polymorphisms in androgen signaling genes predict aggressive epithelial ovarian cancer biology
Authors: Dimitry L. Lerner, Daniel R. Scoles, Beth Y. Karlan, Andrew J. Li
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

1852 

Purpose: The androgen receptor (AR) harbors a polymorphic CAG repeat sequence in exon 1, coding for a polyglutamine tract whose length inversely correlates with AR transactivation function. AIB1, an steroid receptor co-activator, expresses a similar polymorphic glutamine sequence within the carboxy-terminal coding region. We hypothesize that genotypic variations in the androgen signaling pathway promote aggressive epithelial ovarian cancer biology, and sought to examine AR-AIB1 interactions in malignant ovarian epithelial cells and to determine the impact of AR and AIB1 genotype on clinical outcome. Experimental Design. AR-null SKOV-3 cells were stably transfected with AR and subjected to confocal laser scanning microscopy (CLSM) after treatment with dihydrotestosterone (DHT). Cells were labeled with monoclonal anti-AR and anti-AIB1 antibodies. Genotype analysis of the AR and AIB1 CAG repeat regions was performed on 89 patients with epithelial ovarian cancer. Medical records were reviewed for clinico-pathologic factors and survival. Data were examined using the Chi-squared test and Kaplan-Meier survival and Cox Regression analyses. Results: Nuclear translocation of AIB1 was identified on CLSM with expression of AR. Co-localization studies also suggested direct interaction between AR and AIB1. Patients with short AR and AIB1 genotype (  62 months, p = 0.01). After controlling for age, stage, grade, and suboptimal cytoreduction, multivariate analysis identified the presence of short AR - AIB1 genotype as an independent poor prognostic factor for overall survival ( p = 0.05). Conclusions: These data suggest AR and AIB1 directly interact in malignant epithelial ovarian cells, and that this combination of short genotypes in key proteins of the androgen signaling pathway may promote an aggressive phenotype of epithelial ovarian cancer.
Modern Sulfonylureas: Dangerous or Wrongly Accused?
Authors: Matthew C. Riddle
Journal: Diabetes Care (2017)

Except for insulin, sulfonylureas and biguanides are the best studied and most widely used glucose-lowering agents. However, neither class of drugs has had an easy life because of concern about safety. Phenformin, a biguanide, was associated with lactic acidosis and withdrawn from use (1) after causing increased mortality in the University Group Diabetes Program (UGDP) (2). The UGDP also found a sulfonylurea, tolbutamide, to be associated with increased mortality (3). Since then, a newer biguanide, metformin, has risen to its current place as the leading oral therapy for diabetes based on its relative lack of hazard from lactic acidosis and evidence, especially from a subgroup of participants in the UK Prospective Diabetes Study (UKPDS), that it can reduce cardiovascular risk and mortality (4,5). Even though the main randomized comparison in the UKPDS (sulfonylurea or insulin vs. lifestyle therapy) showed that cholorpropamide, glyburide, or glipizide also can reduce medical risks (5,6), the reputation of all sulfonylureas has remained tarnished. A warning of “increased risk of cardiovascular mortality” remains in their labeling information. Treatment guidelines and publications reporting effects of new drugs in other classes often emphasize the risk of hypoglycemia and weight gain from sulfonylureas. And yet, at least 25% of patients with type 2 diabetes are using sulfonylureas (7,8), presumably because they are very inexpensive, allow once-daily oral dosing, reliably reduce glucose, and rarely cause symptomatic side effects other than hypoglycemia. More than 40 years after the UGDP, their risks versus benefits are still debated (9–11). Statistical assessments of data pooled from randomized studies and clinical databases continue to be published, with conflicting …
A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective
Authors: Christopher J. Ryerson, Tamera J. Corte, Joyce S. Lee, Luca Richeldi, Simon L. F. Walsh, Jeffrey L. Myers, Jürgen Behr, Vincent Cottin, Sonye K. Danoff, Kevin R. Flaherty, David J. Lederer, David A. Lynch, Fernando J. Martinez, Ganesh Raghu, William D. Travis, Zarir Udwadia, Athol U. Wells, Harold R. Collard
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
A Case of Acute Yellow Atrophy of the Liver
Authors: C. T. Anderson
Journal: BMJ (1900)

LIVER.[ , o 1371 or sigmoid gut can be made to reach the caecum except by the aid of very violent massage.Co-existence of Enterie Fever and Dysentery.-Theco-exist- ence of enteric fever with dysentery was more than once unexpectedly disclosed in our mortuary tent, and I am per- mitted to state that the medical returns of the hospital will show how very often the two diseases occur, if not simultane- ously, within a short interval of one another.When co- existent the cardinal symptoms of either are certainly much modified, and it is in these cases especially that Widal's react'on has been of the greatest service to us.
Contribution of health care factors to the burden of skin disease in the United States
Authors: Henry W. Lim, Scott A.B. Collins, Jack S. Resneck, Jean L. Bolognia, Julie A. Hodge, Thomas A. Rohrer, Marta J. Van Beek, David J. Margolis, Arthur J. Sober, Martin A. Weinstock, David R. Nerenz, Wendy Smith Begolka, Jose V. Moyano
Journal: Journal of the American Academy of Dermatology (2017)
HIF-1α Dependent Wound Healing Angiogenesis In Vivo Can Be Controlled by Site-Specific Lentiviral Magnetic Targeting of SHP-2
Authors: Yvonn Heun, Kristin Pogoda, Martina Anton, Joachim Pircher, Alexander Pfeifer, Markus Woernle, Andrea Ribeiro, Petra Kameritsch, Olga Mykhaylyk, Christian Plank, Florian Kroetz, Ulrich Pohl, Hanna Mannell
Journal: Molecular Therapy (2017)

Hypoxia promotes vascularization by stabilization and activation of the hypoxia inducible factor 1α (HIF-1α), which constitutes a target for angiogenic gene therapy. However, gene therapy is hampered by low gene delivery efficiency and non-specific side effects. Here, we developed a gene transfer technique based on magnetic targeting of magnetic nanoparticle-lentivirus (MNP-LV) complexes allowing site-directed gene delivery to individual wounds in the dorsal skin of mice. Using this technique, we were able to control HIF-1α dependent wound healing angiogenesis in vivo via site-specific modulation of the tyrosine phosphatase activity of SHP-2. We thus uncover a novel physiological role of SHP-2 in protecting HIF-1α from proteasomal degradation via a Src kinase dependent mechanism, resulting in HIF-1α DNA-binding and transcriptional activity in vitro and in vivo. Excitingly, using targeting of MNP-LV complexes, we achieved simultaneous expression of constitutively active as well as inactive SHP-2 mutant proteins in separate wounds in vivo and hereby specifically and locally controlled HIF-1α activity as well as the angiogenic wound healing response in vivo. Therefore, magnetically targeted lentiviral induced modulation of SHP-2 activity may be an attractive approach for controlling patho-physiological conditions relying on hypoxic vessel growth at specific sites.
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus
Authors: Chi Chiu Mok, Ling Yin Ho, Sau Mei Tse, Kar Li Chan
Journal: Annals of the Rheumatic Diseases (2017)

To study the prevalence of remission and its effect on damage and quality of life (QOL) in Chinese patients with systemic lupus erythematosus (SLE).Patients who fulfilled ≥4 American College of Rheumatology criteria for SLE were identified. Their remission status at last clinic visits was determined by the European consensus criteria (complete/clinical remission ± immunosuppressive drugs). The increase in SLE damage index (SDI) in the preceding 5 years was compared between patients who were and were not in remission for ≥5 years. QOL of patients as assessed by the validated Chinese version of the Medical Outcomes Study Short-Form-36 (SF36) and the LupusPRO was also compared between the remission and non-remission groups by statistical analysis.769 SLE patients were studied (92% women; age: 46.4±14.6 years; SLE duration: 12.6±8.1 years). At last visit, clinical remission was present in 259 (33.7%) patients and complete remission was present in 280 (36.4%) patients. Clinical and complete remissions for ≥5 years were achieved in 64 (8.3%) and 129 (16.8%) of the patients, respectively. Patients remitted for ≥5 years were older, and had significantly lower prevalence of renal involvement, leucopenia or thrombocytopaenia. Fifty-three (6.9%) patients in remission ≥5 years were taken off all medications, including hydroxychloroquine (HCQ) (drug-free). Patients who remitted for ≥5 years but off-therapy (except HCQ) had significantly less SDI increment than those who did not remit (0.17±0.53 vs 0.67±1.10; p<0.001). Among 453 patients who had QOL assessment, remission for ≥5 years was associated with significantly higher SF36 and the total health-related scores of the LupusPRO.Durable remission can be achieved in a quarter of patients with SLE. Patients with remission for ≥5 years have significantly less damage accrual and better QOL. Prolonged remission is an appropriate criterion for outcome assessment in SLE.
TCTAP A-083 NOGA System-based Electromechanical Assessment of Left Ventricular Systolic Rotation Pattern in Patients with Heart Failure
Authors: Tomasz Jadczyk, Jacek Wilczek, Hanspeter Fisher, Zofia Parma, Maximilian Emmert, Magdalena Cyulska, Tomasz Pawlowski, Anna Blach, Jolanta Biernat, Krzysztof S. Golba, Wojciech Wojakowski
Journal: Journal of the American College of Cardiology (2017)
TCTAP C-172 A Patient with High SYNTAX Score and Chronic Total Occlusion Who Was Able to be Treated by the Bi-radial Approach Using 7Fr GLIDESHEATH
Authors: Takayuki Yabe, Toshiya Muramatsu, Masatsugu Nakano, Hideyuki Takimura
Journal: Journal of the American College of Cardiology (2017)
The diagnosis and management of NK/T-cell lymphomas
Authors: Eric Tse, Yok-Lam Kwong
Journal: Journal of Hematology & Oncology (2017)

Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-cell origin, with a minority deriving from the T-cell lineage. Pathologically, the malignancy occurs in two forms, extranodal NK/T-cell lymphoma, nasal type; and aggressive NK-cell leukaemia. Lymphoma occur most commonly (80%) in the nose and upper aerodigestive tract, less commonly (20%) in non-nasal areas (skin, gastrointestinal tract, testis, salivary gland), and rarely as disseminated disease with a leukemic phase. Genetic analysis showed mutations of genes involved in the JAK/STAT pathway, RNA assembly, epigenetic regulation, and tumor suppression. In initial clinical evaluation, positron emission tomography computed tomography, and quantification of plasma EBV DNA are mandatory as they are useful for response monitoring and prognostication. In stage I/II diseases, combined chemotherapy and radiotherapy (sequentially or concurrently) is the best approach. Conventional anthracycline-containing regimens are ineffective and should be replaced by non-anthracycline-containing regimens, preferably including L-asparaginase. Radiotherapy alone is associated with high systemic relapse rates and should be avoided. In stage III/IV diseases, non-anthracycline-regimens-containing L-asparaginase are the standard. In relapsed/refractory cases, blockade of the programmed death protein 1 has recently shown promising results with high response rates. In the era of effective non-anthracycline-containing regimens, autologous haematopoietic stem cell transplantation (HSCT) has not been shown to be beneficial. However, allogeneic HSCT may be considered for high-risk or advanced-stage patients in remission or relapsed/refractory patients responding to salvage therapy. Prognostic models taking into account presentation, interim, and end-of-treatment parameters are useful in triaging patients to different treatment strategies.
Hypertension Disparities
Authors: Herman A. Taylor, Gari D. Clifford, Makia E. Powers
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Plasma membrane activatable polymeric nanotheranostics with self-enhanced light-triggered photosensitizer cellular influx for photodynamic cancer therapy
Authors: Hao-Ran Jia, Yao-Wen Jiang, Ya-Xuan Zhu, Yan-Hong Li, Hong-Yin Wang, Xiaofeng Han, Zhi-Wu Yu, Ning Gu, Peidang Liu, Zhan Chen, Fu-Gen Wu
Journal: Journal of Controlled Release (2017)
Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation
Authors: Latt S. Mansor, Maria da Luz Sousa Fialho, Georgina Yea, Will A. Coumans, James A. West, Matthew Kerr, Carolyn A. Carr, Joost J.F.P. Luiken, Jan F.C. Glatz, Rhys D. Evans, Julian L. Griffin, Damian J. Tyler, Kieran Clarke, Lisa C. Heather
Journal: Cardiovascular Research (2017)

The type 2 diabetic heart oxidizes more fat and less glucose, which can impair metabolic flexibility and function. Increased sarcolemmal fatty acid translocase (FAT/CD36) imports more fatty acid into the diabetic myocardium, feeding increased fatty acid oxidation and elevated lipid deposition. Unlike other metabolic modulators that target mitochondrial fatty acid oxidation, we proposed that pharmacologically inhibiting fatty acid uptake, as the primary step in the pathway, would provide an alternative mechanism to rebalance metabolism and prevent lipid accumulation following hypoxic stress.Hearts from type 2 diabetic and control male Wistar rats were perfused in normoxia, hypoxia and reoxygenation, with the FAT/CD36 inhibitor sulfo-N-succinimidyl oleate (SSO) infused 4 min before hypoxia. SSO infusion into diabetic hearts decreased the fatty acid oxidation rate by 29% and myocardial triglyceride concentration by 48% compared with untreated diabetic hearts, restoring fatty acid metabolism to control levels following hypoxia-reoxygenation. SSO infusion increased the glycolytic rate by 46% in diabetic hearts during hypoxia, increased pyruvate dehydrogenase activity by 53% and decreased lactate efflux rate by 56% compared with untreated diabetic hearts during reoxygenation. In addition, SSO treatment of diabetic hearts increased intermediates within the second span of the Krebs cycle, namely fumarate, oxaloacetate, and the FAD total pool. The cardiac dysfunction in diabetic hearts following decreased oxygen availability was prevented by SSO-infusion prior to the hypoxic stress. Infusing SSO into diabetic hearts increased rate pressure product by 60% during hypoxia and by 32% following reoxygenation, restoring function to control levels.Diabetic hearts have limited metabolic flexibility and cardiac dysfunction when stressed, which can be rapidly rectified by reducing fatty acid uptake with the FAT/CD36 inhibitor, SSO. This novel therapeutic approach not only reduces fat oxidation but also lipotoxicity, by targeting the primary step in the fatty acid metabolism pathway.